SCI Pharmtech (Taiwan) Performance
| 4119 Stock | TWD 95.50 2.10 2.15% |
SCI Pharmtech has a performance score of 12 on a scale of 0 to 100. The firm has a beta of 0.066, which indicates not very significant fluctuations relative to the market. As returns on the market increase, SCI Pharmtech's returns are expected to increase less than the market. However, during the bear market, the loss of holding SCI Pharmtech is expected to be smaller as well. SCI Pharmtech now has a risk of 0.78%. Please validate SCI Pharmtech downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to decide if SCI Pharmtech will be following its existing price patterns.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in SCI Pharmtech are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, SCI Pharmtech may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 633 M | |
| Total Cashflows From Investing Activities | -539.6 M |
SCI |
SCI Pharmtech Relative Risk vs. Return Landscape
If you would invest 8,850 in SCI Pharmtech on August 29, 2024 and sell it today you would earn a total of 700.00 from holding SCI Pharmtech or generate 7.91% return on investment over 90 days. SCI Pharmtech is generating 0.1239% of daily returns and assumes 0.7788% volatility on return distribution over the 90 days horizon. Simply put, 6% of stocks are less volatile than SCI, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SCI Pharmtech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SCI Pharmtech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SCI Pharmtech, and traders can use it to determine the average amount a SCI Pharmtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | 4119 | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.78 actual daily | 6 94% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average SCI Pharmtech is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SCI Pharmtech by adding it to a well-diversified portfolio.
SCI Pharmtech Fundamentals Growth
SCI Stock prices reflect investors' perceptions of the future prospects and financial health of SCI Pharmtech, and SCI Pharmtech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SCI Stock performance.
| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 9.19 B | |||
| Shares Outstanding | 95.38 M | |||
| Price To Earning | 14.98 X | |||
| Price To Book | 2.62 X | |||
| Price To Sales | 11.33 X | |||
| Revenue | 864.22 M | |||
| EBITDA | 129.25 M | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 12.73 X | |||
| Total Debt | 3.65 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 37.30 X | |||
| Cash Flow From Operations | 280.28 M | |||
| Earnings Per Share | 2.13 X | |||
| Total Asset | 4.19 B | |||
| Retained Earnings | 809 M | |||
| Current Asset | 1.8 B | |||
| Current Liabilities | 782 M | |||
About SCI Pharmtech Performance
Evaluating SCI Pharmtech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SCI Pharmtech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SCI Pharmtech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and specialty chemicals in Taiwan. SCI Pharmtech, Inc. was founded in 1987 and is based in Taoyuan City, Taiwan. SCI PHARMTECH operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about SCI Pharmtech performance evaluation
Checking the ongoing alerts about SCI Pharmtech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SCI Pharmtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 49.0% of the company shares are owned by insiders or employees |
- Analyzing SCI Pharmtech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SCI Pharmtech's stock is overvalued or undervalued compared to its peers.
- Examining SCI Pharmtech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SCI Pharmtech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SCI Pharmtech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SCI Pharmtech's stock. These opinions can provide insight into SCI Pharmtech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.